# Lower early-stage rectal cancer surgical approaches: therapeutic options and cancer biomarker alterations

## TL;DR

A new surgical approach combining simplified transanal excision and a hemorrhoid procedure may be a safer and more affordable option for early-stage rectal cancer.

## Contribution

The study introduces a simplified surgical technique for early-stage rectal cancer that is less costly and technically demanding than traditional methods.

## Key findings

- The sTE + RPH group had less intraoperative bleeding, lower costs, and fewer complications compared to TEM.
- CDK2/4/6, FOXD1, and PAK4 expression levels varied between groups and may be linked to recurrence risk.
- The new technique is a feasible alternative for treating early-stage rectal cancer in resource-limited settings.

## Abstract

Low early-stage rectal cancer (LeREC), typically referring to pTis and pT1 tumors without nodal involvement or lymphovascular/perineural invasion and confined to the mucosa, can potentially be treated with transanal local excision techniques. While transanal endoscopic microsurgery (TEM) remains a common minimally invasive option, it is technically demanding and costly. There remains a need for safer, simpler, and more accessible alternatives.

To evaluate the safety and efficacy of a simplified transanal excision (sTE) combined with the Ruiyun procedure for hemorrhoids (RPH) compared to conventional TEM in the treatment of LeREC.

In this randomized, controlled study, 48 patients with LeREC located within 12 cm of the anal verge were assigned to receive either TEM (n = 20) or sTE combined with RPH (n = 28). Surgical outcomes and postoperative complications were compared. Immunohistochemical analyses of CDK2, CDK4, CDK6, FOXD1, and PAK4 were performed on primary tumor tissues to investigate potential biomarkers associated with tumor recurrence.

All patients were followed up for 12 months. The sTE + RPH group showed reduced intraoperative bleeding, lower surgical costs, and fewer complications compared to the TEM group. Expression levels of CDK2/4/6, FOXD1, and PAK4 were observed to vary between groups and were potentially associated with recurrence risk.

The combination of sTE and RPH may offer a safe, cost-effective, and feasible alternative to TEM for treating LeREC, particularly in resource-limited settings. It facilitates wider clinical application without compromising curative efficacy.